Delivery Order SPE2DR25D3301-SPE2DR26F18TL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,363.00 to AmerisourceBergen Drug Corp for FORTEO 560 mcg/2.24 ml pen injections. This order, issued on June 18, 2025, with an ultimate completion date of June 20, 2025, represents a firm fixed price delivery under a competitive, non-set-aside procurement. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,748.30 to AmerisourceBergen Drug Corp for FORTEO 560 micrograms per 2.24 milliliter pen injections. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of October 27, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for FORTEO 560 MCG/2.24 ML pen injections valued at $6,024.75, with an ultimate completion date of November 12, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the pharmaceutical distributor for medical supply procurement supporting federal healthcare needs. The contract was performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $11,404.44 to AmerisourceBergen Drug Corp for the supply of FORTEO 560 MCG/2.24 ML pen injections on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $11,376.94 delivery order to AmerisourceBergen Drug Corp for FORTEO (560 mcg/2.24 mL pen injections) on December 3, 2025, with completion by December 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $55,993.09 to AmerisourceBergen Drug Corp for FORTEO (forteoide) 560 micrograms per 2.24 milliliters pen injections on August 19, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,057.77 to AmerisourceBergen Drug Corp for the supply of FORTEO 560 MCG/2.24 ML pen injections on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $7,230.60 delivery order to AmerisourceBergen Drug Corp for FORTEO 560 MCG/2.24 ML pen injections on November 20, 2025, with completion expected by November 21, 2025. This firm fixed-price contract represents a pediatric delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The award was competitively made with no set-aside designation, and...
- The Defense Logistics Agency awarded a delivery order valued at $2,601.43 to AmerisourceBergen Drug Corp for FORTEO 560 MCG/2.24 ML pen injections on July 21, 2025, with completion targeted for July 22, 2025. This firm fixed price contract, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $2,601.43 firm fixed-price delivery order to AmerisourceBergen Drug Corp for FORTEO (Fortified Growth Factor) 560 MCG/2.24 ML pen injections on June 18, 2025, with completion targeted for June 20, 2025. This non-set-aside contract represents a small-value pharmaceutical procurement to support federal medical supply needs. The award was fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F18TLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for FORTEO 560 MCG/2.24 ML pen injections valued at $88,100.58 on November 28, 2025. This firm fixed-price delivery order, with an ultimate completion date of December 1, 2025, represents a non-competitive award under an existing contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company serves as the pharmaceutical distributor for federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs. FORTEO, a brand-name pharmaceutical product, falls within the company's portfolio of specialty medications and supports the Defense Health Agency and other federal healthcare systems. AmerisourceBergen's selection reflects its established capability as a critical vendor in the federal medical supply chain, with consistent performance across multiple therapeutic domains and delivery modalities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $88.1k | 11/27/25 |